Viking Therapeutics (1VT) Ratios
76 Followers
Viking Therapeutics Ratios
DE:1VT's free cash flow for Q3 2026 was $-138.19M. For the 2026 fiscal year, DE:1VT's free cash flow was increased by $0.00 and operating cash flow was $-138.19M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 9.33 | 33.09 | 19.19 | 7.61 | 23.98 |
| Quick Ratio | 9.33 | 33.09 | 19.19 | 7.61 | 23.98 |
| Cash Ratio | 2.16 | 0.97 | 2.90 | 1.67 | 3.00 |
| Solvency Ratio | -4.69 | -3.91 | -4.27 | -2.95 | -6.23 |
| Operating Cash Flow Ratio | -3.64 | -3.20 | -3.83 | -2.21 | -5.42 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 638.93M | $ 879.17M | $ 347.15M | $ 143.83M | $ 201.75M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.12 | 1.03 | 1.06 | 1.16 | 1.04 |
| Debt Service Coverage Ratio | 0.00 | -1165.14 | -1142.44 | -1187.53 | -3077.00 |
| Interest Coverage Ratio | 0.00 | -1605.54 | -1145.76 | -1192.46 | -3093.44 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.01 | 0.01 | 0.02 | 0.00 |
| Net Debt to EBITDA | 0.46 | 0.23 | 0.54 | 0.50 | 0.48 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 91.43% | 72.86% | 85.19% | 97.89% | 98.76% |
| Return on Assets (ROA) | -50.25% | -12.11% | -23.31% | -40.86% | -26.10% |
| Return on Equity (ROE) | -56.28% | -12.49% | -24.65% | -47.39% | -27.24% |
| Return on Capital Employed (ROCE) | -61.55% | -17.13% | -28.86% | -48.00% | -27.58% |
| Return on Invested Capital (ROIC) | -61.54% | -17.12% | -28.83% | -47.90% | -27.58% |
| Return on Tangible Assets | -50.25% | -12.11% | -23.31% | -40.86% | -26.10% |
| Earnings Yield | -9.07% | -2.51% | -4.89% | -9.54% | -15.49% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -45096.55 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 45096.55 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.47 | -0.81 | -0.78 | -0.63 | -0.62 |
| Free Cash Flow Per Share | -2.47 | -0.81 | -0.78 | -0.63 | -0.62 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -2034.20 | -78.45 | -58.23 | -30.94 | -1640.90 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -7.03% | -2.00% | -4.18% | -6.70% | -13.40% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -11.03 | -39.84 | -20.44 | -10.49 | -6.46 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 6.20 | 4.98 | 5.04 | 4.97 | 1.76 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -14.22 | -49.98 | -23.93 | -14.92 | -7.46 |
| Price-to-Operating Cash Flow Ratio | -14.22 | -49.98 | -23.93 | -14.92 | -7.46 |
| Price-to-Earnings Growth (PEG) Ratio | -0.05 | -3.63 | -6.00 | -0.41 | -0.16 |
| Enterprise Value Multiple | -10.57 | -39.83 | -16.92 | -9.81 | -5.94 |
| Enterprise Value | 3.80B | 4.36B | 1.70B | 687.17M | 328.77M |
| EV to EBITDA | -10.57 | -39.83 | -16.92 | -9.81 | -5.94 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -13.63 | -49.69 | -23.19 | -14.20 | -6.91 |
| EV to Operating Cash Flow | -13.63 | -49.69 | -23.19 | -14.20 | -6.91 |
| Tangible Book Value Per Share | 5.67 | 8.07 | 3.69 | 1.89 | 2.62 |
| Shareholders’ Equity Per Share | 5.67 | 8.07 | 3.69 | 1.89 | 2.62 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -3.19 | -1.01 | -0.91 | -0.90 | -0.71 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.85 | 0.98 | 0.99 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.77 | 0.80 | 0.85 | 0.70 | 0.87 |
Currency in USD
